Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NVO 
Novo Nordisk A/S (NVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: NVO (2-star) is a SELL. SELL since 3 days. Simulated Profits (-6.74%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $62.33
1 Year Target Price $62.33
| 4 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.85% | Avg. Invested days 66 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 237.02B USD | Price to earnings Ratio 13.72 | 1Y Target Price 62.33 |
Price to earnings Ratio 13.72 | 1Y Target Price 62.33 | ||
Volume (30-day avg) 12 | Beta 0.33 | 52 Weeks Range 44.54 - 110.70 | Updated Date 10/24/2025 |
52 Weeks Range 44.54 - 110.70 | Updated Date 10/24/2025 | ||
Dividends yield (FY) 3.24% | Basic EPS (TTM) 3.88 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 35.61% | Operating Margin (TTM) 43.52% |
Management Effectiveness
Return on Assets (TTM) 21.82% | Return on Equity (TTM) 79.17% |
Valuation
Trailing PE 13.72 | Forward PE 14.08 | Enterprise Value 271799261274 | Price to Sales(TTM) 0.76 |
Enterprise Value 271799261274 | Price to Sales(TTM) 0.76 | ||
Enterprise Value to Revenue 5.54 | Enterprise Value to EBITDA 11.2 | Shares Outstanding 3368558040 | Shares Floating 3187938882 |
Shares Outstanding 3368558040 | Shares Floating 3187938882 | ||
Percent Insiders 0.01 | Percent Institutions 9.31 |
Upturn AI SWOT
Novo Nordisk A/S
Company Overview
History and Background
Novo Nordisk A/S was founded in 1923 in Denmark. Initially focused on insulin production, it has grown into a global leader in diabetes care, obesity treatment, and other serious chronic diseases. Significant milestones include the development of innovative insulin delivery systems and GLP-1 receptor agonists.
Core Business Areas
- Diabetes Care: Novo Nordisk develops and manufactures insulin and oral antidiabetic drugs for the treatment of diabetes. This includes a wide range of insulin analogues, GLP-1 receptor agonists, and other diabetes medications.
- Obesity Care: The company offers medications for chronic weight management, including GLP-1 receptor agonists. This segment is experiencing rapid growth driven by increasing obesity rates.
- Biopharmaceuticals: This segment includes treatments for growth disorders and rare blood disorders. Products include growth hormone, hemophilia treatments, and hormone replacement therapies.
Leadership and Structure
Novo Nordisk A/S is led by a board of directors and an executive management team. The company operates globally with regional offices and manufacturing facilities across multiple countries. Lars Fruergaard Ju00f8rgensen is the current CEO.
Top Products and Market Share
Key Offerings
- Ozempic (Semaglutide): A GLP-1 receptor agonist for type 2 diabetes and also used for weight loss. It has a significant market share in the GLP-1 RA market. Competitors include Eli Lilly's Trulicity and Mounjaro.
- Rybelsus (Oral Semaglutide): The first oral GLP-1 receptor agonist for type 2 diabetes. Competitors include other oral diabetes medications such as metformin and sulfonylureas.
- Wegovy (Semaglutide): A higher dose of semaglutide specifically for chronic weight management. Competitors include Saxenda (liraglutide), also by Novo Nordisk, and other weight loss drugs.
- Tresiba (Insulin Degludec): A long-acting basal insulin for diabetes. Competitors include Lantus (insulin glargine) and Levemir (insulin detemir) from Sanofi.
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in diabetes and obesity care, is experiencing significant growth. The aging population and rising prevalence of chronic diseases drive demand. Increased research into novel treatments is also fueling expansion.
Positioning
Novo Nordisk is a market leader in diabetes and obesity care. The company has a strong reputation for innovation and high-quality products, providing a competitive advantage.
Total Addressable Market (TAM)
The global diabetes and obesity market is estimated to be in the hundreds of billions of dollars. Novo Nordisk is well-positioned to capture a significant portion of this market with its diverse portfolio and innovative products.
Upturn SWOT Analysis
Strengths
- Strong market position in diabetes and obesity care
- Innovative product portfolio
- Global presence
- High R&D investment
- Strong brand reputation
Weaknesses
- Reliance on a few key products
- Exposure to pricing pressures
- Patent expirations
- Competition from biosimilars
- Supply chain vulnerabilities
Opportunities
- Expanding into emerging markets
- Developing new treatments for related conditions
- Acquiring complementary businesses
- Leveraging digital health technologies
- Collaborating with other pharmaceutical companies
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Drug pricing regulations
- Negative clinical trial results
Competitors and Market Share
Key Competitors
- LLY
- SNY
- NVO
Competitive Landscape
Novo Nordisk has a strong position in diabetes and obesity care but faces competition from other large pharmaceutical companies. Its focus on innovation and strong brand reputation gives it an advantage. However, competitors are also investing heavily in R&D and marketing, creating a competitive landscape.
Major Acquisitions
Dicerna Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions): 3300
- Strategic Rationale: Expanded Novo Nordisk's capabilities in RNAi therapeutics for cardiometabolic diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data available in Company Financial Statements
Future Projections: Analyst estimates are available from financial news sources.
Recent Initiatives: Recent initiatives can be found on company website, such as research partnerships and market expansion
Summary
Novo Nordisk exhibits strong fundamentals due to its leading position in the diabetes and obesity market. The company's innovative products drive revenue growth and profitability. Pricing pressure and competition remain potential challenges. Overall, Novo Nordisk is a well-positioned company with a promising growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Novo Nordisk Investor Relations
- Company Financial Statements
- Analyst Reports
- Industry News Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novo Nordisk A/S
Exchange NYSE | Headquaters - | ||
IPO Launch date 1982-01-04 | President, CEO & Member of the Management Board Mr. Maziar Mike Doustdar | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 78387 | Website https://www.novonordisk.com |
Full time employees 78387 | Website https://www.novonordisk.com | ||
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.